Precision medicine (PM) is a medical model that proposes the customization of healthcare - with medical decisions, practices, and/or products being tailored to the individual patient. In this model, diagnostic testing is often employed for selecting appropriate and optimal therapies based on the context of a patient’s genetic content or other molecular or cellular analysis. Tools employed in PM can include molecular diagnostics, imaging, and analytics/software.
Relationship to Personalized Medicine
In explaining the distinction from a similar common term of personalized medicine, the National Research Council explains, "Precision Medicine refers to the tailoring of medical treatment to the individual characteristics of each patient. It does not literally mean the creation of drugs or medical devices that are unique to a patient, but rather the ability to classify individuals into subpopulations that differ in their susceptibility to a particular disease, in the biology and/or prognosis of those diseases they may develop, or in their response to a specific treatment. Preventive or therapeutic interventions can then be concentrated on those who will benefit, sparing expense and side effects for those who will not. Although the term ‘Personalized Medicine’ is also used to convey this meaning, that term is sometimes misinterpreted as implying that unique treatments can be designed for each individual."
Often, though not necessarily, PM involves the application of panomic analysis and systems biology to analyze the cause of an individual patient's disease at the molecular level and then to utilize targeted treatments (possibly in combination) to address that individual patient's disease process. The patient's response is then tracked as closely as possible, often using surrogate measures such as tumor load (v. true outcomes, such as 5 year survival rate), and the treatment finely adapted to the patient's response. The branch of precision medicine that addresses cancer is referred to as "precision oncology".
Inter-personal difference of molecular pathology is diverse, so as inter-personal difference in the exposome, which influence disease processes through the interactome within the tissue microenvironment, differentially from person to person. As the theoretical basis of precision medicine, the "unique disease principle" emerged to embrace the ubiquitous phenomenon of heterogeneity of disease etiology and pathogenesis. The unique disease principle was first described in neoplastic diseases as the unique tumor principle. As the exposome is a common concept of epidemiology, precision medicine is intertwined with molecular pathological epidemiology (MPE). MPE research is capable of identifying potential biomarkers for precision medicine.
Ability to provide precision medicine to patients in routine clinical testing depends on the availability of molecular profiling tests. For example, test individual germline DNA. Many different aspects of precision medicine are tested in research settings (e.g., proteome, microbiom), but routine practice may not use all available inputs. Ability to practice precision medicine is also dependent on the available knowledge bases available to assist clinician in taking action based on test results.
- Evidence-based medicine
- Molecular medicine
- Molecular diagnostics
- Molecular pathology
- Molecular pathological epidemiology
- Personalized medicine
- Unique disease principle
- Blau, CA, Liakopoulou, E (2013). "Can we deconstruct cancer, one patient at a time?". Trends in Genetics 29 (1): 6–10. doi:10.1016/j.tig.2012.09.004.
- Levi A. Garraway, Jaap Verweij and Karla V. Ballman (2013). "Precision Oncology: An Overview". J. Clinical Oncology 31 (15): 1803–1805. doi:10.1200/jco.2013.49.4799.
- Ogino S, Lochhead P, Chan AT, Nishihara R, Cho E, Wolpin BM, Meyerhardt AJ, Meissner A, Schernhammer ES, Fuchs CS, Giovannucci E. Molecular pathological epidemiology of epigenetics: emerging integrative science to analyze environment, host, and disease. Mod Pathol 2013;26:465-484.
- Ogino S, Fuchs CS, Giovannucci E. How many molecular subtypes? Implications of the unique tumor principle in personalized medicine. Expert Rev Mol Diagn 2012; 12: 621-628.
- Ogino S, Lochhead P, Giovannucci E, Meyerhardt JA, Fuchs CS, Chan AT. Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology. Oncogene advance online publication 24 June 2013; doi: 10.1038/onc.2013.244
- Huser, V; Sincan, M; Cimino, J. J. (2014). "Developing genomic knowledge bases and databases to support clinical management: Current perspectives". Pharmacogenomics and Personalized Medicine 7: 275–83. doi:10.2147/PGPM.S49904. PMC 4175027. PMID 25276091.